[go: up one dir, main page]

PE20080056A1 - Derivados de cromencarboxamida como antagonistas del receptor s1p1 - Google Patents

Derivados de cromencarboxamida como antagonistas del receptor s1p1

Info

Publication number
PE20080056A1
PE20080056A1 PE2007000430A PE2007000430A PE20080056A1 PE 20080056 A1 PE20080056 A1 PE 20080056A1 PE 2007000430 A PE2007000430 A PE 2007000430A PE 2007000430 A PE2007000430 A PE 2007000430A PE 20080056 A1 PE20080056 A1 PE 20080056A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
chromencarboxamide
receptor
carboxamide
Prior art date
Application number
PE2007000430A
Other languages
English (en)
Inventor
Rolf Baenteli
Nigel Gramham Cooke
Sven Weiler
Frederic Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080056A1 publication Critical patent/PE20080056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

REFERIDA A UN DERIVADO DE CROMENCARBOXAMIDA DE FORMULA (I), DONDE R1 Y R2 SON H, HALOGENO, NITRO, ALQUILO C1-C8, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO C1-C8, ENTRE OTROS; R4 ES ALQUILO C1-C2-NRcRd, DONDE Rc Y Rd SON H, ALQUILO C1-C8, CICLOALQUILO C3-C6, ENTRE OTROS; R5 ES OH, ALQUILO C1-C8, H, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[4-(AMINO-METIL)-FENIL]-7-METOXI-2-OXO-8-PROPIL-2H-CROMEN-3-CARBOXAMIDA, 7-(2-FLUORO-ETOXI)-N-{4-[(METIL-AMINO)-METIL]-FENIL}-2-OXO-8-PROPIL-2H-CROMEN-3-CARBOXAMIDA, N-[4-(AMINO-METIL)-2-(TRIFLUORO-METIL)-FENIL]-7-ETOXI-2-OXO-8-PROPIL-2H-CROMEN-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR S1P1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS MEDIADOS POR LINFOCITOS, ENFERMEDADES AUTOINMUNES, DIABETES TIPO I O II, ENTRE OTRAS
PE2007000430A 2006-04-12 2007-04-10 Derivados de cromencarboxamida como antagonistas del receptor s1p1 PE20080056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607389.4A GB0607389D0 (en) 2006-04-12 2006-04-12 Organic compounds

Publications (1)

Publication Number Publication Date
PE20080056A1 true PE20080056A1 (es) 2008-03-26

Family

ID=36571719

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000430A PE20080056A1 (es) 2006-04-12 2007-04-10 Derivados de cromencarboxamida como antagonistas del receptor s1p1

Country Status (16)

Country Link
US (1) US20090318546A1 (es)
EP (1) EP2010511A1 (es)
JP (1) JP2009534315A (es)
KR (1) KR20090004945A (es)
CN (1) CN101421260A (es)
AR (1) AR060401A1 (es)
AU (1) AU2007236114B2 (es)
BR (1) BRPI0710130A2 (es)
CA (1) CA2644951A1 (es)
CL (1) CL2007001023A1 (es)
GB (1) GB0607389D0 (es)
MX (1) MX2008013123A (es)
PE (1) PE20080056A1 (es)
RU (1) RU2008144487A (es)
TW (1) TW200815387A (es)
WO (1) WO2007115820A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008221A (es) * 2007-02-02 2009-08-12 Novartis Ag Antagonista de receptor de cromeno s1p1.
BRPI0916812B8 (pt) 2008-07-23 2022-10-18 Arena Pharm Inc Derivados do ácido 1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético substituído úteis no tratamento de distúrbios autoimunes e inflamatórios, seu uso, composição farmacêutica que os compreende e processo de preparação
PT2342205T (pt) 2008-08-27 2016-07-28 Arena Pharm Inc Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios
KR101102952B1 (ko) * 2009-03-05 2012-01-10 주식회사 문인 크린룸용 창문 프레임
KR20120075481A (ko) 2009-10-23 2012-07-06 알러간, 인코포레이티드 치료적 유용성을 갖는 수용체 조절제로서 쿠마린 화합물
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
CN102884064B (zh) 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
WO2014130572A1 (en) * 2013-02-21 2014-08-28 Allergan, Inc. Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
CN103265517B (zh) * 2013-05-11 2016-01-13 浙江大学 3-取代香豆素类衍生物及其用途
ES2534336B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
ES2534318B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
EA202091742A1 (ru) 2018-02-27 2021-02-19 Артакс Биофарма Инк. ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN108715589B (zh) * 2018-06-19 2021-04-20 华侨大学 一种用作caspase-3激活剂的香豆素类衍生物及其应用
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN111747917B (zh) * 2020-07-28 2022-09-13 遵义医科大学 一种蛇床子素酰胺类化合物及其应用
CN113402491A (zh) * 2021-06-15 2021-09-17 山东大学苏州研究院 一种香豆素酰胺类化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763944B1 (fr) * 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
AU2003239155B2 (en) * 2002-04-19 2008-12-04 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CN1506359A (zh) * 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
WO2005028472A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents

Also Published As

Publication number Publication date
MX2008013123A (es) 2008-10-21
JP2009534315A (ja) 2009-09-24
KR20090004945A (ko) 2009-01-12
CA2644951A1 (en) 2007-10-18
AU2007236114B2 (en) 2010-12-02
BRPI0710130A2 (pt) 2011-08-02
WO2007115820A1 (en) 2007-10-18
CL2007001023A1 (es) 2008-03-14
EP2010511A1 (en) 2009-01-07
GB0607389D0 (en) 2006-05-24
AU2007236114A1 (en) 2007-10-18
CN101421260A (zh) 2009-04-29
TW200815387A (en) 2008-04-01
RU2008144487A (ru) 2010-05-20
US20090318546A1 (en) 2009-12-24
AR060401A1 (es) 2008-06-11

Similar Documents

Publication Publication Date Title
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20080069A1 (es) Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20081263A1 (es) DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
PE20091473A1 (es) Heterociclos como inhibidores de esteaoril-coa desaturasa
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
PE20090487A1 (es) Compuestos heterociclos como inhibidores de lta4h
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20090839A1 (es) Derivados de isoxazol-imidazol
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal